IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit grows in line with its trailing trend

Q3 FY2026 gross profit of $764.3M rose 11.8% year over year, behind the +13.7% change in trailing-twelve-month gross profit. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Gross profit amounted to 61.8% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.8% toward the trailing-twelve-month pace of +13.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$764.3M-1.9% QoQ
Last fiscal yearDec 2025
$2.66B+11.8% YoY
LTMSep 2026
$2.92B+13.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.8%——
1 year+11.8%——
3-year CAGR+9.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
2.66B USD
Year-over-year change
+11.8%
4-year CAGR
+8.9%

Gross Profit vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 gross profit of $2.92B is the 3rd highest of the 5 companies compared; the peer median is $4.75B.
  • Its year-over-year change of +13.7% is the 3rd highest of 5, against a peer median of +9.5%.
  • Gross profit amounts to 62.7% of revenue for IDXX, versus a peer median of 62.2%.
IDXX Competitors Peer median
Gross Profit for IDXX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$50.05B +4.1%+3.7%75.4%
ZTSZoetis Inc.LTM Jun 2026$6.75B +2.6%+6.8%70.9%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$2.92B +13.7%+9.9%62.7%
ELANElanco Animal Health IncorporatedLTM Sep 2026$2.75B +29.3%+1.3%53.5%
NEOGNeogen CorporationLTM Aug 2026$418.98M +14.9%+0.2%47.4%
Peer median (excluding IDXX) $4.75B+9.5%+2.5%62.2%

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.22B3.37B3.66B3.9B4.3B
Cost of Revenue1.33B1.36B1.47B1.52B1.64B
Gross Profit1.89B2B2.19B2.38B2.66B
Gross Margin58.8%59.5%59.8%61.0%61.8%
Research & Development161.01M254.82M190.95M219.79M251.21M
Selling, General & Admin796.4M850.75M901.89M1.03B1.05B
Operating Expenses957.4M1.11B1.09B1.25B1.3B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
EBITDA1.04B1.01B1.22B1.28B1.51B
EBITDA Margin32.3%30.1%33.3%32.7%35.0%
Operating Income932.03M898.77M1.1B1.13B1.36B
Operating Margin29.0%26.7%30.0%29.0%31.6%
Interest Income434K1.07M5.63M12.7M2.42M
Interest Expense29.81M39.86M41.58M31.21M38.27M
Other Income / Expenses(29.37M)(38.79M)(35.95M)(18.51M)(35.84M)
Income Before Tax902.65M859.97M1.06B1.11B1.32B
Pre-Tax Margin28.1%25.5%29.0%28.5%30.8%
Income Tax Expense157.81M180.88M216.13M221.96M264.73M
Net Income744.85M679.09M845.04M887.87M1.06B
Net Margin23.2%20.2%23.1%22.8%24.6%
EPS (Basic)8.748.1210.1710.7713.17
EPS (Diluted)8.608.0310.0610.6713.08
Weighted Avg Shares85.2M83.62M83.07M82.47M80.1M
Weighted Avg Shares (Diluted)86.57M84.6M83.98M83.25M80.68M

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.